Ruxolitinib cream is a topical formulation of ruxolitinib, a selective inhibitor of JAK1 and JAK2. Itch-free state was also assessed stratified by baseline itch NR.

**Patients**
- **Study Design and Patients**
  - Eligible patients were aged ≥12 years with AD and sustained an itch-free state vs vehicle (p=0.0021).

**Conclusions**
- A significantly greater number of patients treated with ruxolitinib cream achieved an itch-free state vs vehicle during the 8-week treatment period.
- Patients who applied ruxolitinib cream had a substantially shorter median time to itch NR 0/1 vs vehicle.

**Disclosure**
- All authors served as consultants or received research grants or other honoraria from AbbVie, Amgen, Arista, AstraZeneca, Bausch Health, DERMED, Eli Lilly and Company, Evoluscent, Farmaka, Galderma, Incyte Corporation, Janssen, LEO Pharma, Menlo Therapeutics, Regeneron, Roche, and UCB Pharma.
- An advisory board for AbbVie, Amgen, Arista, AstraZeneca, Bausch Health, DERMED, Eli Lilly and Company, Evoluscent, Farmaka, Galderma, Incyte Corporation, Janssen, LEO Pharma, Menlo Therapeutics, Regeneron, Roche, and UCB Pharma was held to discuss the data presented.
- The authors have no other relevant financial relationships with commercial interests to disclose.

**Reference**